8-K: Gain Therapeutics Provides Operational Update and Outlines Key Milestones for 2025

Gain Therapeutics announces progress in its GT-02287 Parkinson's disease program, including the initiation of a Phase 1b clinical trial and plans for future development.

Summary

• Gain Therapeutics provided an operational update and outlined key milestones expected in 2025.
• The company is advancing the clinical development of GT-02287 for Parkinson's disease, with a Phase 1b clinical trial expected to begin imminently in Australia.
• A study in healthy volunteers demonstrated the safety and tolerability of GT-02287, with a 53% increase in GCase activity observed.
• The company expects to provide an enrollment update for the Phase 1b trial by the end of 1Q 2025 and discuss interim analysis in 2Q 2025.
• The Phase 1b trial will enroll 15-20 individuals with either GBA1 or idiopathic Parkinson's disease, receiving oral GT-02287 daily for three months.
• Gain Therapeutics is also focused on strengthening its collaboration with the FDA to expand the clinical development of GT-02287 within the U.S.
• As of September 30, 2024, the company had approximately $12M in cash and cash equivalents, expected to finance operations through the interim analysis of the Phase 1b trial in 2Q 2025.
• The company remains opportunistic with respect to ongoing discussions with potential licensing partners and evaluating other sources of financing.
• Gain Therapeutics believes its Phase 1b clinical trial will illustrate the broad neuroprotective effect demonstrated in pre-clinical models of Parkinsons disease will translate to human participants with Parkinsons disease.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with progress in clinical trials and encouraging feedback from the FDA. However, the need for future funding and the inherent risks of drug development temper the overall sentiment.

Positives

• GT-02287 demonstrated safety and tolerability in a study with healthy volunteers.
• The study showed a 53% increase in GCase activity in peripheral blood samples.
• The FDA provided encouraging feedback and did not identify significant regulatory hurdles for Phase 2 preparations.
• The company has approximately $12M in cash and cash equivalents as of September 30, 2024.
• The company is in discussions with potential licensing partners and evaluating other sources of financing.

Risks

• The company's cash is expected to finance operations only through the interim analysis of the Phase 1b clinical trial, expected during 2Q 2025.
• The company will need to secure additional funding to commence planning for Phase 2 studies, anticipated in 2H 2025.
• The success of the Phase 1b clinical trial is not guaranteed, and results may not translate to human participants.

Future Outlook

The company expects to provide an enrollment update for the Phase 1b trial by the end of 1Q 2025 and discuss interim analysis in 2Q 2025. They anticipate commencing planning for Phase 2 studies in 2H 2025.

Management Comments

• President and CEO Gene Mack stated that 2025 is poised to be another pivotal year for Gain Therapeutics.
• Gene Mack expressed gratitude for the strong support received from the Parkinson's community.
• Gene Mack stated that the company believes its Phase 1b clinical trial will illustrate the broad neuroprotective effect demonstrated in pre-clinical models of Parkinsons disease will translate to human participants with Parkinsons disease.

Industry Context

Parkinson's disease is the second most common neurodegenerative disease after Alzheimer's, and there are currently only symptomatic treatments available. Gain Therapeutics aims to develop a disease-modifying therapy.

Comparison to Industry Standards

• The 53% increase in GCase activity observed in the healthy volunteer study is a positive indicator of target engagement, which is a key factor in the development of effective therapies for Parkinson's disease.
• Other companies developing therapies for Parkinson's disease include Denali Therapeutics, Biogen, and Roche. Gain Therapeutics' approach of using allosteric modulators to restore protein function is a unique approach that could potentially offer advantages over other therapies.

Management Changes

Stakeholder Impact

• Shareholders: The update provides information on the company's progress and future plans, which could impact the stock price.
• Patients: The development of GT-02287 could potentially provide a new treatment option for Parkinson's disease.
• Employees: The company's progress could lead to job security and growth opportunities.

Next Steps

• Begin dosing the first patients in the Phase 1b clinical trial in Australia.
• Provide an enrollment update for the Phase 1b trial by the end of 1Q 2025.
• Discuss interim analysis of the Phase 1b clinical trial in 2Q 2025.
• Complete ongoing six and nine month chronic animal tox studies during 2Q 2025 and 3Q 2025, respectively.
• Commence planning for Phase 2 studies in 2H 2025.
• Continue strengthening collaboration with the FDA.
• Continue discussions with potential licensing partners and evaluate other sources of financing.

Key Dates